Tridek-One, Paris, June 17, 2019 – Tridek One, a biotech company specialized in the development of products for the treatment of immune disorders, announces today the appointment of Dr. Philippe Berthon as Chief Executive Officer.
Philippe Berthon has more than 25 years of experience in biotechnology in various management positions, including R&D and corporate finance, through his role as CEO of Aurgalys (2008-2018), Vaxon-Biotech (2004-2008) and Urogene (1998-2004). Previously, Dr. Berthon was Co-Founder and Director of the Onco-Urology Research Laboratory at the Saint-Louis Hospital in Paris (1995-1999), Postdoctoral Research Fellow at the University of York Cancer Research Unit (1991-1995). Dr. Berthon has co-authored more than 50 peer-reviewed international publications, obtained his PhD in Reproductive Physiology from Paris Pierre and Marie Curie University (1991), and is a graduate of the HEC Challenge + Business and Administration program (2001).
“We are very pleased to welcome Philippe on board Tridek One. Philippe brings a rare blend of experience. This is of great value for Tridek One and the preparation of its future Series A.” says Alain Huriez, Chairman of the Board.
“Joining such a talented scientific team already supported by leading European venture funds as Advent France Biotechnology and Advent Life Sciences is a really challenging opportunity” says Philippe Berthon, “I am truly delighted to start acting with Tridek-One team and projects, with the aim to develop a new therapeutic class in the immunology field”
Founded in 2018 by Dr. Giuseppina Caligiuri and Professor Antonino Nicoletti, researchers in INSERM Unit 1148, located at Bichat Hospital in Paris, together with Advent France Biotechnology, Tridek-One is developing a novel CD31 agonist approach to modulate immune activation and so provide a new way to manage inflammatory conditions. Tridek-One has recently announced a 3M€ funding supported by two venture funds, Advent France Biotechnology and Advent Life Sciences (UK). For more information, please visit www.tridekone.com.
About Advent France Biotechnology
Advent France Biotechnology is a French Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward. The firm works with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and drive inventive Life Sciences start-ups to success. Advent France Biotechnology Seed Fund I stands as the first dedicated Life Sciences seed-fund in France. For more information, please visit www.adventfb.com
About Advent Life Sciences (UK)
Advent Life Sciences is one of Europe’s leading venture teams investing in life sciences businesses. The team consists of professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The firm invests in a range of sectors within life sciences, principally in new drug discovery, enabling technologies and med tech. For more information, please visit www.adventls.com.
Press Contacts ALIZE RP:
Caroline Carmagnol et Aurore Gangloff
email@example.com – +33 6 64 18 99 59
firstname.lastname@example.org – + 33 6 49 57 82 68
email@example.com – +33 6 07 43 18 72
Website : www.tridekone.com
Twitter : @TridekOne